A global leader in cannabis cultivation and branding seeking to transform from a loss-making grower into a profitable consumer lifestyle brand through international expansion and cost optimization.
Investors might buy this stock anticipating a turnaround as the company matures its brand portfolio and potentially achieves profitability through strategic cost cuts or a successful acquisition. The current valuation reflects deep value for a company with tangible assets worth over $900M and a clear path to exit its current debt load of roughly $300M. Any positive regulatory shift in the US could unlock significant multiple expansion for the global cannabis leader.
The stock carries high risk due to persistent losses of nearly $600M annually and a massive retained earnings deficit exceeding $10B, suggesting fundamental business model issues remain unresolved. With revenue declining year-over-year for three consecutive years, the company faces an existential threat of bankruptcy if it cannot generate positive free cash flow soon. High interest expense of $74.6M further drains liquidity, making the company vulnerable to any credit tightening or further regulatory setbacks.
Canopy Growth Corp is a leading global cannabis producer operating primarily in North America with an expanding international footprint. The company leverages its vertically integrated model to produce high-quality flower, edibles, concentrates, and branded products across regulated markets. With a focus on research and development alongside commercial scaling, the firm aims to capture growth opportunities in the evolving legal cannabis industry.
Despite a significant reduction in losses compared to previous years, the company continues to report substantial net operating losses as it navigates a challenging revenue contraction from $402.9M in 2023 to $269.0M in 2025. The management team is prioritizing deleveraging and operational efficiency to stabilize cash flow, though the negative cash flow from operations of $165.8M indicates ongoing capital intensity in maintaining inventory levels at $96.4M.
The legal cannabis industry is transitioning from a boom-and-bust phase into a consolidation era where only the most efficient producers with strong brand equity will survive long-term price wars. While market sizes continue to grow in Canada and select US states, saturation of local markets is driving down wholesale prices and compressing margins for traditional growers. Success now depends on building direct-to-consumer brands and diversifying revenue streams beyond just flower sales.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $402.9M | $297.1M | $269.0M |
| Cost of Revenue | $507.0M | $216.3M | $189.5M |
| Gross Profit | $-104.1M | $80.9M | $79.5M |
| Operating Expenses | $2.74B | $309.6M | $196.7M |
| Operating Income | $-2.85B | $-228.7M | $-117.1M |
| R&D | $21.7M | $4.6M | $2.7M |
| G&A | $456.2M | $229.4M | $169.6M |
| Stock-Based Comp | $31.2M | $14.2M | $-4.2M |
| Depreciation | $56.7M | $28.4M | $21.5M |
| Amortization | $27.8M | $24.8M | $21.6M |
| Other OpEx | $2.27B | $75.6M | $24.3M |
| Non-Operating Income | $-466.0M | $-242.6M | $-479.9M |
| Interest Expense | $126.2M | $105.4M | $74.6M |
| Pre-Tax Income | $-3.31B | $-471.4M | $-597.0M |
| Income Tax | $-4.8M | $12.3M | $7.1M |
| Continuing Ops | $-3.31B | $-483.7M | $-604.1M |
| Discontinued Ops | $0 | $-192.1M | $6.0M |
| Net Income | $-3.31B | $-675.8M | $-598.1M |
| Minority Interest | $-31.4M | $0 | $0 |
| Net to Common | $-3.28B | $-675.8M | $-598.1M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $1.08B | $371.2M | $294.6M |
| Cash & Equivalents | $677.0M | $170.3M | $113.8M |
| Marketable Securities | $105.6M | $33.2M | $17.7M |
| Accounts Receivable | $66.8M | $44.9M | $47.5M |
| Inventory | $148.9M | $77.3M | $96.4M |
| Prepaid Expenses | $40.0M | $23.2M | $7.5M |
| Other Current Assets | $38.9M | $22.3M | $11.7M |
| Long-Term Assets | $1.36B | $929.1M | $623.1M |
| PP&E (Net) | $499.5M | $320.1M | $293.5M |
| Intangibles | $188.7M | $104.1M | $87.2M |
| Goodwill | $85.6M | $43.2M | $46.0M |
| Operating Leases | $20.7M | $7.2M | $4.6M |
| Other LT Assets | $567.4M | $454.6M | $191.8M |
| Total Assets | $2.44B | $1.30B | $917.7M |
| Current Liabilities | $803.8M | $234.7M | $94.4M |
| Accounts Payable | $76.2M | $28.7M | $26.1M |
| Current Debt | $556.9M | $103.9M | $4.3M |
| Current Leases | $9.1M | $11.7M | $7.5M |
| Other Current Liab | $161.6M | $90.4M | $56.6M |
| Long-Term Liabilities | $875.2M | $565.1M | $336.1M |
| Long-Term Debt | $750.0M | $493.3M | $299.8M |
| LT Operating Leases | $41.0M | $23.1M | $15.7M |
| Other LT Liab | $84.3M | $48.7M | $20.6M |
| Total Liabilities | $1.68B | $799.8M | $430.5M |
| Shareholders' Equity | $760.0M | $500.5M | $487.2M |
| Retained Earnings | $-9.67B | $-10.33B | $-10.93B |
| AOCI | $-13.9M | $-16.1M | $535.0K |
| Total L&E | $2.44B | $1.30B | $917.7M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-3.31B | $-675.8M | $-598.1M |
| Non-Cash Adjustments | $2.78B | $379.6M | $431.4M |
| Working Capital Changes | $-30.6M | $14.3M | $997.0K |
| Cash from Operations | $-557.5M | $-281.9M | $-165.8M |
| Capital Expenditures | $9.2M | $3.4M | $10.8M |
| Cash from Investing | $433.4M | $241.6M | $-47.8M |
| Debt Issuances | $135.2M | — | $68.3M |
| Debt Repayments | $118.2M | $509.8M | $100.0M |
| Cash from Financing | $-19.7M | $-465.1M | $148.7M |
| FX Effect | $44.9M | $-1.3M | $8.4M |
| Net Change in Cash | $-99.0M | $-506.7M | $-56.5M |
| Beginning Cash | $776.0M | $677.0M | $170.3M |
| Ending Cash | $677.0M | $170.3M | $113.8M |
The company's revenue is driven by its core Cannabis segment, which includes flower, extracts, edibles, and other products sold across Canada and the US; this is supported by a growing Cannabis Lifestyle segment featuring apparel, accessories, and beverages designed to build a consumer brand beyond simple plant sales.
1. Prolonged regulatory uncertainty in key US states affecting potential interstate commerce and federal legality. 2. Intense competition from well-funded legacy pharmaceutical companies and established local growers squeezing margins. 3. High fixed costs and inventory write-downs risk if demand growth does not outpace production scaling.
1. Vertically integrated supply chain allowing for better margin control from seed to shelf. 2. Strong proprietary IP portfolio including patented strains and unique product formulations that differentiate the brand in a crowded market. 3. Significant cash reserves and access to capital markets providing flexibility for acquisitions or strategic pivots during volatile price cycles.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.